ZURICH, Oct 21 (Reuters) - Actelion (ATLN.VX) announced an 800 million Swiss franc ($829 million) share buyback on Thursday and reiterated it wants to stay independent, knocking hopes the Swiss biotech group could be sold and sending its shares lower.
